Canada Sees Face-Off Over Higher-Strength Adalimumab
Jamp And Alvotech Go Head-To-Head With Celltrion On 100mg/ml Biosimilar Humira
Hot on the heels of rival Celltrion, Jamp and partner Alvotech have now launched their own higher-strength adalimumab biosimilar in Canada, setting up a showdown between their Simlandi version and Celltrion’s Yuflyma.
You may also be interested in...
Alvotech has swiftly advanced in Japan and Canada, as part of its mission to introduce its pipeline of biosimilars across the globe.
Alvotech has appointed a new chief quality officer in the wake of manufacturing deficiencies being identified by the US FDA. Meanwhile, multiple executives have departed from Hikma’s management team, with one joining Lupin as chief scientific officer.
Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.